756 related articles for article (PubMed ID: 21570509)
1. Rationale and design of the Anti-Xa therapy to lower cardiovascular events in addition to standard therapy in subjects with acute coronary syndrome-thrombolysis in myocardial infarction 51 (ATLAS-ACS 2 TIMI 51) trial: a randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of rivaroxaban in subjects with acute coronary syndrome.
Gibson CM; Mega JL; Burton P; Goto S; Verheugt F; Bode C; Plotnikov A; Sun X; Cook-Bruns N; Braunwald E
Am Heart J; 2011 May; 161(5):815-821.e6. PubMed ID: 21570509
[TBL] [Abstract][Full Text] [Related]
2. Rivaroxaban in patients stabilized after a ST-segment elevation myocardial infarction: results from the ATLAS ACS-2-TIMI-51 trial (Anti-Xa Therapy to Lower Cardiovascular Events in Addition to Standard Therapy in Subjects with Acute Coronary Syndrome-Thrombolysis In Myocardial Infarction-51).
Mega JL; Braunwald E; Murphy SA; Plotnikov AN; Burton P; Kiss RG; Parkhomenko A; Tendera M; Widimsky P; Gibson CM
J Am Coll Cardiol; 2013 May; 61(18):1853-9. PubMed ID: 23500262
[TBL] [Abstract][Full Text] [Related]
3. Reduction of stent thrombosis in patients with acute coronary syndromes treated with rivaroxaban in ATLAS-ACS 2 TIMI 51.
Gibson CM; Chakrabarti AK; Mega J; Bode C; Bassand JP; Verheugt FW; Bhatt DL; Goto S; Cohen M; Mohanavelu S; Burton P; Stone G; Braunwald E;
J Am Coll Cardiol; 2013 Jul; 62(4):286-90. PubMed ID: 23602776
[TBL] [Abstract][Full Text] [Related]
4. Rivaroxaban versus placebo in patients with acute coronary syndromes (ATLAS ACS-TIMI 46): a randomised, double-blind, phase II trial.
Mega JL; Braunwald E; Mohanavelu S; Burton P; Poulter R; Misselwitz F; Hricak V; Barnathan ES; Bordes P; Witkowski A; Markov V; Oppenheimer L; Gibson CM;
Lancet; 2009 Jul; 374(9683):29-38. PubMed ID: 19539361
[TBL] [Abstract][Full Text] [Related]
5. Comparison of the efficacy and safety of two rivaroxaban doses in acute coronary syndrome (from ATLAS ACS 2-TIMI 51).
Mega JL; Braunwald E; Wiviott SD; Murphy SA; Plotnikov A; Gotcheva N; Ruda M; Gibson CM
Am J Cardiol; 2013 Aug; 112(4):472-8. PubMed ID: 23711804
[TBL] [Abstract][Full Text] [Related]
6. A randomized trial to compare the safety of rivaroxaban vs aspirin in addition to either clopidogrel or ticagrelor in acute coronary syndrome: The design of the GEMINI-ACS-1 phase II study.
Povsic TJ; Roe MT; Ohman EM; Steg PG; James S; Plotnikov A; Mundl H; Welsh R; Bode C; Gibson CM
Am Heart J; 2016 Apr; 174():120-8. PubMed ID: 26995378
[TBL] [Abstract][Full Text] [Related]
7. Clinically significant bleeding with low-dose rivaroxaban versus aspirin, in addition to P2Y12 inhibition, in acute coronary syndromes (GEMINI-ACS-1): a double-blind, multicentre, randomised trial.
Ohman EM; Roe MT; Steg PG; James SK; Povsic TJ; White J; Rockhold F; Plotnikov A; Mundl H; Strony J; Sun X; Husted S; Tendera M; Montalescot G; Bahit MC; Ardissino D; Bueno H; Claeys MJ; Nicolau JC; Cornel JH; Goto S; Kiss RG; Güray Ü; Park DW; Bode C; Welsh RC; Gibson CM
Lancet; 2017 May; 389(10081):1799-1808. PubMed ID: 28325638
[TBL] [Abstract][Full Text] [Related]
8. Novel oral anticoagulants in acute coronary syndrome.
Costopoulos C; Niespialowska-Steuden M; Kukreja N; Gorog DA
Int J Cardiol; 2013 Sep; 167(6):2449-55. PubMed ID: 22989603
[TBL] [Abstract][Full Text] [Related]
9. The ATLAS ACS 2-TIMI 51 trial and the burden of missing data: (Anti-Xa Therapy to Lower Cardiovascular Events in Addition to Standard Therapy in Subjects With Acute Coronary Syndrome ACS 2-Thrombolysis In Myocardial Infarction 51).
Krantz MJ; Kaul S
J Am Coll Cardiol; 2013 Aug; 62(9):777-81. PubMed ID: 23747777
[TBL] [Abstract][Full Text] [Related]
10. Rivaroxaban in patients with a recent acute coronary syndrome.
Mega JL; Braunwald E; Wiviott SD; Bassand JP; Bhatt DL; Bode C; Burton P; Cohen M; Cook-Bruns N; Fox KA; Goto S; Murphy SA; Plotnikov AN; Schneider D; Sun X; Verheugt FW; Gibson CM;
N Engl J Med; 2012 Jan; 366(1):9-19. PubMed ID: 22077192
[TBL] [Abstract][Full Text] [Related]
11. Safety and efficacy of rivaroxaban for the secondary prevention following acute coronary syndromes among biomarker-positive patients: Insights from the ATLAS ACS 2-TIMI 51 trial.
Korjian S; Braunwald E; Daaboul Y; Verheugt F; Bode C; Tendera M; Jain P; Plotnikov A; Burton P; Gibson CM
Eur Heart J Acute Cardiovasc Care; 2019 Mar; 8(2):186-193. PubMed ID: 29249166
[TBL] [Abstract][Full Text] [Related]
12. Discharge aspirin dose and clinical outcomes in patients with acute coronary syndromes treated with prasugrel versus clopidogrel: an analysis from the TRITON-TIMI 38 study (trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrel-thrombolysis in myocardial infarction 38).
Kohli P; Udell JA; Murphy SA; Cannon CP; Antman EM; Braunwald E; Wiviott SD
J Am Coll Cardiol; 2014 Jan; 63(3):225-32. PubMed ID: 24140678
[TBL] [Abstract][Full Text] [Related]
13. The effect of rivaroxaban on myocardial infarction in the ATLAS ACS 2 - TIMI 51 trial.
Cavender MA; Gibson CM; Braunwald E; Wiviott SD; Murphy SA; Toda Kato E; Plotnikov AN; Amuchástegui M; Oude Ophuis T; van Hessen M; Mega JL
Eur Heart J Acute Cardiovasc Care; 2015 Oct; 4(5):468-74. PubMed ID: 25318481
[TBL] [Abstract][Full Text] [Related]
14. The role of rivaroxaban in atrial fibrillation and acute coronary syndromes.
Reddy P; Giugliano RP
J Cardiovasc Pharmacol Ther; 2014 Nov; 19(6):526-32. PubMed ID: 24659084
[TBL] [Abstract][Full Text] [Related]
15. Usefulness of Rivaroxaban for Secondary Prevention of Acute Coronary Syndrome in Patients With History of Congestive Heart Failure (from the ATLAS-ACS-2 TIMI-51 Trial).
Korjian S; Braunwald E; Daaboul Y; Mi M; Bhatt DL; Verheugt FWA; Cohen M; Bode C; Burton P; Plotnikov AN; Gibson CM
Am J Cardiol; 2018 Dec; 122(11):1896-1901. PubMed ID: 30340765
[TBL] [Abstract][Full Text] [Related]
16. Fatal or Irreversible Bleeding and Ischemic Events With Rivaroxaban in Acute Coronary Syndrome.
Gibson CM; Levitan B; Gibson WJ; Yee MK; Murphy SA; Yuan Z; Chakrabarti AK; Lee M; Braunwald E
J Am Coll Cardiol; 2018 Jul; 72(2):129-136. PubMed ID: 29976285
[TBL] [Abstract][Full Text] [Related]
17. Rivaroxaban in acute coronary syndromes--is it prime time?
Asrar ul Haq M; van Gaal WJ
Expert Rev Cardiovasc Ther; 2014 Jun; 12(6):649-58. PubMed ID: 24746010
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of prasugrel compared with clopidogrel in patients with acute coronary syndromes: design and rationale for the TRial to assess Improvement in Therapeutic Outcomes by optimizing platelet InhibitioN with prasugrel Thrombolysis In Myocardial Infarction 38 (TRITON-TIMI 38).
Wiviott SD; Antman EM; Gibson CM; Montalescot G; Riesmeyer J; Weerakkody G; Winters KJ; Warmke JW; McCabe CH; Braunwald E;
Am Heart J; 2006 Oct; 152(4):627-35. PubMed ID: 16996826
[TBL] [Abstract][Full Text] [Related]
19. Rivaroxaban: a review of its use in acute coronary syndromes.
Plosker GL
Drugs; 2014 Mar; 74(4):451-64. PubMed ID: 24535922
[TBL] [Abstract][Full Text] [Related]
20. An open-label, randomized, controlled, multicenter study exploring two treatment strategies of rivaroxaban and a dose-adjusted oral vitamin K antagonist treatment strategy in subjects with atrial fibrillation who undergo percutaneous coronary intervention (PIONEER AF-PCI).
Gibson CM; Mehran R; Bode C; Halperin J; Verheugt F; Wildgoose P; van Eickels M; Lip GY; Cohen M; Husted S; Peterson E; Fox K
Am Heart J; 2015 Apr; 169(4):472-8.e5. PubMed ID: 25819853
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
